Skip Navigation

Annals of Oncology 2005 16(Supplement 4):iv116-iv122; doi:10.1093/annonc/mdi920
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (7)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by De Marinis, F.
Right arrow Articles by De Petris, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by De Marinis, F.
Right arrow Articles by De Petris, L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 European Society for Medical Oncology

Invited Paper

Neoadjuvant chemotherapy for stage IIIA-N2 non-small cell lung cancer

F. De Marinis1,2,, V. Gebbia3,4 and L. De Petris1

1 5th Pneumo-Oncology Unit, Department of Oncology, San Camillo-Forlanini Hospitals, Rome; 2 Fo.R.O. (Oncological Research Foundation), Rome; 3 Department of Experimental Oncology and Clinical Applications, University of Palermo; 4 Medical Oncology Unit, La Maddalena Clinic for Cancer, Palermo, Italy

Correspondence to: Dr Filippo De Marinis, 5th Pneumo-Oncology Unit, Deparment of Lung Diseases, S. Camillo-Forlanini Hospitals, Via Portuense 332, 00149 Rome, Italy. Tel/Fax: +39 06 55552565; Email: f.demarinis{at}oncpneumo.it

Neoadjuvant chemotherapy in potentially resectable stage IIIA-N2 non-small cell lung cancer (NSCLC) has become standard of treatment in the last years. Two randomised pioneer phase III trials conducted with second generation platinum combinations had demonstrated an advantage in survival of induction chemotherapy followed by surgery versus surgery alone. Subsequently, a wide number of phase II studies with third generation platinum-based doublets or triplets have increased the evidence of the activity as well as the good tolerability of this approach. Nowadays, the main topics of ongoing clinical research are to assess the role of induction chemotherapy in early stage disease, and the role of induction radiotherapy, as well as definite chemo-radiotherapy in stage IIIA NSCLC. This report review these issues and focuses on current treatment options for resectable stage IIIA-N2 NSCLC.

Key words: neoadjuvant chemotherapy, NSCLC, stage IIIA-N2, early stage, neoadjuvant radiotherapy, molecular markers analysis


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Eur Respir JHome page
S. Mohamed, K. Yasufuku, T. Nakajima, K. Hiroshima, M. Chiyo, S. Yoshida, M. Suzuki, Y. Sekine, K. Shibuya, G. Agamy, et al.
Nuclear survivin in pN2 nonsmall cell lung cancer: prognostic and clinical implications
Eur. Respir. J., January 1, 2009; 33(1): 127 - 133.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.